白雲山(600332.SH):公司將繼續拓展中藥產品國際市場
格隆匯7月18日丨有投資者向白雲山(600332.SH)提問:公司是否有考慮將中藥產品發展到海外市場?
白雲山回覆:隨着中醫藥獲世界越來越多國家的認可,中藥國際化進程也在不斷推進。公司華佗再造丸於20世紀90年代已進入國際市場,目前海外銷售已佈局至俄羅斯、越南等全球多個國家和地區。近年,部分子公司獲得了海外場地認證,也有中藥產品獲得海外的產品註冊證書,為公司中藥業務開拓海外市場起到積極作用。未來,公司將繼續拓展中藥產品國際市場,積極推進產品海外註冊及推動已獲產品註冊的國家和地區的市場銷售工作,助力公司和大南藥板塊海外市場發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.